{
    "symbol": "PTCT",
    "quarter": 4,
    "year": 2022,
    "date": "2023-02-21 22:35:24",
    "content": " Your line is open. I think, from what we reported in January, we are seeing the overall response rate up from 61% to 65% and magnitude of Phe reduction for both the non-classical and classical PKU patients is also higher, which continues to give us a lot of confidence going into Part 2. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. No, we're -- look, it's a nice aspect of AADC deficiency and the gene therapy that we have as we see it is truly a transformational therapy where -- and as you've seen that all of the patients perform better in their patients that obviously, while they were growth arrested and weren't able to hold their head up, turn over, sit up, stand or talk have changed. Your line is open. So, I think the -- so I think maybe -- so just so we're clear, the reason is it was the end of the study really occurs when it's the last patient last visit, you've completed that aspect of the study, and that's when all the patients are completed, you can then go and clean the data and ultimately get it analyzed."
}